Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 01, 2015 2:27 AM ET

Biotechnology

Company Overview of IGXBio, Inc.

Company Overview

IGXBio, Inc., a biotechnology company, develops DNA immunotherapies for HIV infection. Its DNA immunotherapies reduce dependency on anti-HIV drug cocktails and diminish the emergence of drug-resistant HIV strains. The company offers GenePro (?4SHIVku2), a DNA therapeutic incorporating a DNA composition that yields high levels of gene expression and non-infectious HIV protein production, and induces an antibody and cellular immune response in animal models, including non-human primates. It’s therapeutic DNA vaccine generates viral like particles to allow the body to develop killer T cells and memory T cells related to HIV. IGXBio, Inc. was formerly known as ImmunoGenetix Therapeutics, Inc. Th...

8527 Bluejacket Street

Lenexa, KS 66214

United States

Founded in 2001

Phone:

888-744-9246

Fax:

888-744-9246

Key Executives for IGXBio, Inc.

Chief Executive Officer, President and Director
Compensation as of Fiscal Year 2015.

IGXBio, Inc. Key Developments

Cannabis Science, Inc. Enters into Joint Development Agreement with IGXBio, Inc

On May 21, 2015, Cannabis Science, Inc. (the Company), entered into a Joint Development Agreement with IGXBio, Inc., a Delaware corporation (IGXB). Pursuant to the Agreement the Company and IGXB will jointly develop and conduct a clinical protocol for an anti-inflammatory utilizing cannabinoids and GenePro, a DNA based immunotherapy with a FDA IND number. Each company will retain ownership of their respective intellectual property and equally own any new products or drugs derived from the Agreement. The term of the Agreement is initially for 4 years with an automatic renewal provision. The Company will issue IGXB 5 million shares of restricted common stock pursuant to the Agreement.

IGXBio, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 11:00 AM

IGXBio, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 11:00 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
Parasitix Corporation United States
Inception 4, Inc. United States
Millennium Predictive Medicine, Inc. United States
Proteopure, Inc. United States
ImmuneRegen BioSciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 16, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IGXBio, Inc., please visit www.immunogenetix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.